Phase 3 Trial Planned for Cabozantinib Plus Nivolumab-Ipilimumab in RCC
A double-blind, placebo-controlled phase 3 trial is planned to evaluate cabozantinib plus nivolumab and ipilimumab as first-line treatment for advanced clear cell RCC..
A double-blind, placebo-controlled phase 3 trial is planned to evaluate cabozantinib plus nivolumab and ipilimumab as first-line treatment for advanced clear cell RCC..
A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC.
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.
A phase 3 randomized placebo-controlled trial is recruiting to evaluate nivolumab plus ipilimumab among patients with localized RCC at risk of relapse after nephrectomy.
Modified dosing of lenvatinib-everolimus did not improve tolerability and may have modestly decreased efficacy compared with standard dosing in advanced RCC.
RCC histology was associated with survival after treatment with tremelimumab, according to results of a post hoc analysis of a pilot trial.
Surgical delays due to COVID-19 may be safe for some patients with localized RCC, and are unlikely to compromise survival for some individuals.
Age, marital status, and geographic location tended to influence use of oral anticancer therapy in older patients with metastatic RCC.
The applications are supported by data from the CheckMate -9ER trial that compared nivolumab, a programmed death receptor-1 blocking antibody, plus cabozantinib, a tyrosine kinase inhibitor, to sunitinib.